SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin ($APP) is trending due to a reported SEC probe into its data collection practices, leading to a sharp sell-off. The community is actively debating whether this is a buying opportunity or a sign of deeper issues, with some pointing to short-seller activity and potential overvaluation. Concerns about the company's growth and potential implications for its S&P 500 status are also being discussed.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining attention as the community rallies around its vision of merging culture, creativity, and crypto. Community members are using the phrase "like Bitcoin but way higher" and highlighting its potential for long-term growth and real-world impact. The conversation is also focused on community building, with new members being welcomed.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid speculation of a potential partnership with Tesla, fueled by a teaser video and upcoming announcement from Tesla, driving significant trading volume. The community is actively debating the likelihood of a collaboration and its potential impact, with some focusing on price targets and short squeeze opportunities, while others express skepticism. The surge also highlights broader interest in the electric vertical takeoff and landing (eVTOL) sector, though the companies remain pre-revenue and volatile.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is trending due to conflicting reports regarding potential U.S. government investment in its Greenland rare earth project, with some sources denying a deal while others maintain ongoing interest; this news has fueled volatility and heavy trading volume. Community discussions revolve around the legitimacy of the reports, potential short squeezes, and the long-term value of CRML's rare earth assets in a sector gaining geopolitical attention. Despite the uncertainty, many investors express confidence in the company's prospects and criticize alleged manipulation.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging following news of a major deal with OpenAI, which includes a significant processor purchase and potential equity stake, positioning AMD as a key player in the AI infrastructure race. The community is buzzing about the implications for AMD's competition with Nvidia and the potential for further analyst upgrades, while also debating whether this rally is sustainable given the structure of the agreement.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to FDA breakthrough therapy designation, igniting significant community excitement and speculation about a potential buyout or partnership. Community members are actively discussing the possibility of a short squeeze, fueled by the stock's low float and the potential for further upward movement. Some traders are drawing comparisons to other high-flying biotech stocks and highlighting the potential for continued gains.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending due to speculation around the potential extension of ACA subsidies, with community members weighing the likelihood of an agreement and its impact on the stock. Community sentiment is bullish, with many discussing a potential short squeeze. Some investors view the stock as undervalued within the broader healthcare sector, while others are wary of the company's reliance on federal subsidies.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is trending as community members discuss its bullish momentum and potential short squeeze, particularly after breaking the $5 level. Investors are optimistic about the stock's future, citing a high percentage of holders in profit and upcoming catalysts like the new chip launch and a quantum conference appearance. Some traders are closely watching for further price movement while pointing out potential for dilution at certain price points.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amidst discussions about its high valuation relative to revenue, a common theme among quantum computing stocks like $IONQ and $QBTS. Community members are debating whether current prices reflect future potential or speculative hype, especially given concerns about share dilution and insider selling. Some investors are wary of a potential correction, while others maintain a bullish outlook based on the long-term prospects of quantum computing.

Society Pass, Inc. engages in the operation and acquisition of fintech and e-commerce platforms and mobile applications. It operates through the following segments: Online Food and Beverage (F&B) and Groceries Deliveries, Digital Marketing, Online Ticketing and Reservation, e-Commerce, Telecommunication Reseller, and Merchant Point of Sale (POS). The Online F&B and Groceries Deliveries segment includes the operation of Handycart, Mangan, and Pushkart brands. The Digital Marketing segment involves the engagement with creators and management of platforms. The Online Ticketing and Reservation segment focuses on the sale of domestic and overseas air ticket and global hotel reservations. The e-Commerce segment refers to the operation of an online lifestyle platform under the brand name Leflair. The Telecommunication Reseller segment consists of sales of local mobile phone plans and global internet data provider plans. The Merchant POS segment covers the sale of hardware and software. The company was founded by Luan Thuc Nguyen on June 22, 2018 and is headquartered in Carson City, NV.

Society Pass Inc

SOPA is trending due to a recent analyst upgrade from Ascendiant Capital, with a raised price target generating excitement. Community members are discussing the potential for a significant price surge and the company's perceived undervaluation, comparing it to other high-momentum stocks. However, some traders are cautioning about potential pullbacks or dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy

Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Retail investors are buzzing about Adial Pharmaceuticals after the company announced the issuance of a key U.S. patent, which strengthens its strategy in precision medicine for addiction treatment.&nbsp;The announcement sent shares soaring to $0.78 during Thursday’s session — the stock’s highest level since February.The patent, officially granted on April 15 by the United States Patent and Trademark Office (USPTO), covers a novel method of treating alcohol- and opioid-related disorders using Adial’s investigational therapy, AD04, in patients with specific genetic markers.The company’s approach positions AD04 as a targeted therapy — not a one-size-fits-all solution — marking a significant step forward in the personalized treatment of addiction.The newly issued patent outlines the administration of AD04 to individuals with serotonin-related gene variations, including genotypes of HTR3A, HTR3B, and SLC6A4, such as the LL genotype of 5-HTTLPR, along with SNPs rs1150226, rs17614942, and rs1176713.&nbsp;The claims also include dosing regimens customized to these genetic profiles — a key component of Adial’s precision medicine approach.In addition to alcohol use disorder (AUD), the patent extends to a wide range of related conditions, including alcohol-induced anxiety, bipolar disorder, sexual dysfunction, sleep disturbances, gambling disorder, and alcohol withdrawal.&nbsp;The retail trading community was quick to react on Stocktwits.&nbsp;Sentiment&nbsp;flipped to ‘extremely bullish’ amid ‘extremely high’ message volume, underscoring strong retail engagement.&nbsp;One user said, “Great news today sent it flying,” while another predicted the stock could jump 50% to 100% in after-hours or the following day, calling the initial 11% gain “a bargain.”<stembedurl>https://stocktwits.com/GracebyFaith/message/613308669</stembedurl><stembedurl>https://stocktwits.com/KING_CRUSH/message/613278365</stembedurl>That retail enthusiasm is complemented by positive analyst coverage. According to data from Koyfin, two of the three analysts covering Adial currently rate the stock a ‘Buy,’ with the third assigning a ‘Hold.’&nbsp;Notably, no analysts have issued ‘Sell’ or ‘Strong Sell’ ratings.Despite Thursday’s spike, Adial shares remain down 26.4% year-to-date, underperforming the broader market. In comparison, the Nasdaq is down 1.7%, while the Dow and S&amp;P 500 have declined 3.9% and 4.5%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dirty needles are collected by outreach workers with St. Ann’s Corner of Harm Reduction as they participate in a weekly needle clean-up at a Bronx park that drug users often use on April 23, 2025 in New York City. (Photo by Spencer Platt/Getty Images)

Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring

Adial Pharmaceuticals jumped to its highest level since February after receiving a U.S. patent for its precision medicine approach to treating addiction. The patent supports the use of AD04 in patients with specific genetic markers.

Equity

EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder

Adial Pharmaceuticals progresses to the second cohort in the AD04 pharmacokinetics study for Alcohol Use Disorder. This study, involving up to 30 healthy volunteers, will provide critical insights...

EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder

Adial Pharmaceuticals publishes Phase 3 ONWARD study results in the European Journal of Internal Medicine. The study reveals AD04 significantly reduces heavy drinking days, with adverse events...

Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars Today

On Wednesday, key U.S. stock indexes closed lower, as the Dow Jones Industrial Average fell by 1.1% to 38,461.51, the S&P 500 dropped nearly 1% to 5,160.64, and the Nasdaq ended the day down by 0.8...

12 acciones de salud en movimiento durante la preapertura del 10/04/2024

Acciones al alza
Jaguar Health (NASDAQ:JAGX) avanzaron un 43,99% para establecerse en los 0,13 d lares durante la sesi n del pre-market del mi rcoles.
Adial Pharmaceuticals (NASDAQ:ADIL) ganaron un...

Adial Pharmaceuticals reports FY results

Adial Pharmaceuticals reports FY results...

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 275.8% in March

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL  Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest...

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

Adial Pharmaceuticals Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$0.4015
Prev Close	$0.3984
Open	$0.4077
Dividend Yield	N/A
50-Day Moving Average	$0.3882
Beta	0.82
Avg. Volume	654,965.52
PE Ratio	-0.33

52-Week High	$1.30
52-Week Low	$0.22
Market Capitalization	$8.7M
EPS (Annual)	-$2.72
Price to Book	1.53
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ADIL
Adial Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ADIL News

ADIL Adial Pharmaceuticals Inc